Homebiotech stocks

biotech stocks

ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

December 15, 2022

CLASS ACTION UPDATE for EIGR, VERU and TWST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for EIGR, VERU and TWST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

December 14, 2022

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

December 14, 2022

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 14, 2022

Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade

Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade

December 14, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2023 in Eiger Lawsuit – EIGR

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2023 in Eiger Lawsuit – EIGR

December 14, 2022

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

December 14, 2022

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

December 14, 2022

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

December 14, 2022

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

December 13, 2022

« 1 … 11 12 13 14 15 … 558 »